Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes

Acceleron, Celgene and Collaborators Announce Two Publications in Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes

March 24, 2014

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN), announced the publication of two papers available online today and in the April issue of the journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice. EPO stimulates the proliferation of early-stage red blood cell precursors to form new red blood cells.

BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy

BG Medicine Announces Issuance of Patent Covering Galectin-3 Testing for Cardiac Resynchronization Therapy

March 20, 2014

 WALTHAM, Mar 20, 2014 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. today announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled "Galectin-3 and Cardiac Resynchronization Therapy," to the Company.

Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

Agios Announces Enrollment of First Patient in Phase 1 Study of AG-120 in Advanced Hematologic Malignancies with an IDH1 Mutation

March 19, 2014

Second Agios Clinical Program in the New Field of Cancer Metabolism

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

March 19, 2014

 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc

Black Duck Appoints Mark Fusco to its Board of Directors

Black Duck Appoints Mark Fusco to its Board of Directors

March 18, 2014

Technology Entrepreneur and Executive to Help Drive Next Stage of Growth for Open Source Software Management Market Leader

Quanterix’s Simoa Technology to Detect Blood Biomarker for Concussion in Hockey Players

Quanterix’s Simoa Technology to Detect Blood Biomarker for Concussion in Hockey Players

March 14, 2014

Lexington, Mass. – March 14, 2014 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that JAMA Neurology has published a ground-breaking study in which its Simoa (single molecule array) technology was used to directly measure the brain protein Tau in the blood of athletes who had sustained mild traumatic brain injuries/ concussions. These measurements have never before been possible in blood.

Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors

Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors

March 14, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc.

Tangent Medical Appoints Eric Sandberg to Company President

Tangent Medical Appoints Eric Sandberg to Company President

March 13, 2014

Ann Arbor, MI, (March 13, 2014) – Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products, announced the appointment of Eric Sandberg as company President reporting to CEO Jeff Williams.

“Eric brings a 20-year background in healthcare and medical devices to Tangent with significant experience in senior leadership roles,” said Williams. “He will be responsible for providing day-to-day executive leadership with an initial strong emphasis on assisting our migration from a development stage start up to a commercial entity.”

Flagship Ventures Partner David Berry Named a 2014 Young Global Leader by the World Economic Forum

Flagship Ventures Partner David Berry Named a 2014 Young Global Leader by the World Economic Forum

March 11, 2014

CAMBRIDGE, Mass., March 11, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced that Dr. David Berry, Partner at Flagship Ventures, has been selected by the World Economic Forum as a 2014 Young Global Leader (YGL).

BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers

BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers

March 10, 2014

WALTHAM, Mar 10, 2014 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian Consensus Document on Cardiac Biomarkers published by the Cardiological Society of India. [1] The Consensus Document on Cardiac Biomarkers reviews cardiac blood tests that are available for diagnosis and management in heart failure, and provides recommendations for physicians on their use and utility in caring for heart failure patients.